As a result of a wide-ranging probe into generic drug price fixing, Heritage Pharmaceuticals admitted to conspiring to set prices for a diabetes medicine and will pay more than $7 million to settle civil and criminal charges.

The drug maker worked with several other companies and individuals between April 2014 and December 2015 to fix prices, rig bids, and allocate customers for the glyburide treatment, according to court documents. More than a half dozen other generic drug makers — including Aurobindo and Teva Pharmaceutical (TEVA) — sell a version of glyburide.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy